Oric Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 100
- Market Cap
- $704.7M
- Website
- http://www.oricpharma.com
- Introduction
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Clinical Trials
9
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
- Conditions
- EGFR Exon 20 Insertion MutationsNSCLCSolid TumorsEGFR-mutated NSCLC
- Interventions
- Drug: ORIC-114 Dose 1 + amivantamabDrug: ORIC-114 Dose 2 + amivantamabDrug: ORIC-114 Dose 3 + amivantamab
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT06816992
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Effect of Food on the Pharmacokinetics of ORIC-114
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT06012721
- Locations
- 🇦🇺
Nucleus Network Pty Ltd., 235 Ryrie St, Geelong, Victoria, Australia
🇦🇺Nucleus Network Pty Ltd., Level 5, Burnet Tower, 89 Commercial Rd, Melbourne, Victoria, Australia
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05413421
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Colorado Springs, Colorado, United States
🇺🇸Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸Comprehensive Urologic Care, Lake Barrington, Illinois, United States
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Conditions
- Solid Tumors
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- ORIC Pharmaceuticals Inc.
- Target Recruit Count
- 30
- Registration Number
- 2024-512264-66-00
- Locations
- 🇺🇸
City of Hope, Long Beach, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- ORIC Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT05227144
- Locations
- 🇺🇸
James R. Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸Northside Hospital Cancer Institute, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next
News
ORIC Pharmaceuticals Appoints Kevin Brodbeck as Chief Technical Officer Ahead of Phase 3 Trials
ORIC Pharmaceuticals has appointed Kevin Brodbeck, PhD, as Chief Technical Officer to support the company's transition into late-stage clinical development.
Biotech Industry Faces Wave of Strategic Layoffs as Companies Prioritize Efficiency and Pipeline Focus
Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts.
ORIC Pharmaceuticals Announces Promising Early Data for ORIC-944 and Collaboration for ORIC-114
ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC).
Unicycive and ORIC Pharmaceuticals Receive Buy Ratings Based on Promising Clinical Data
Unicycive Therapeutics' OLC shows promise in treating hyperphosphatemia by reducing pill burden and adverse events, potentially gaining FDA approval by June 2025.
ORIC Pharmaceuticals Presents Promising Data on Cancer Drug Candidates at AACR Meeting
ORIC Pharmaceuticals presented preclinical data on ORIC-944, a PRC2 inhibitor, showing potential as a best-in-class treatment for prostate cancer in combination with AR inhibitors.